Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health is appealing because its 2Q26 results and raised 2026 guidance point to improving earnings power, with adjusted EBITDA now guided to $120 million-$135 million and modeled at about $129 million for 2026, rising to roughly $151 million in 2027. The company’s integrated specialty care and value-based care platform appears well positioned to capture a large, nascent market, while Highmark, Aetna, and the expected ramp of new Performance Suite contracts support roughly 25% revenue growth in 2027. Cost trends in oncology and especially cardiology are moving in the right direction, and payer rate/capitation adjustments help offset prevalence-related pressure, giving the business better visibility into margin maturation and downside protection.

Evolent Health is facing a weaker fundamental setup because guidance is coming in below expectations, client signings are slower than expected, and existing clients are choosing other vendors, which points to pressure in both retention and new business generation. The company also sees the shift to value-based care progressing more slowly, with little help from the government, while Technology & Services is expected to face an approximately 7% membership headwind and an 11% to 12% revenue decline next year as price degradation and scope changes weigh on PMPMs. Although EVH has not included revenue from certain potential contracts in its approximately 25% growth framework, it does not expect equivalent EBITDA relief if those contracts do not materialize, reinforcing downside risk to margins and execution.